RT Journal Article SR Electronic T1 Molecular Imaging in Cancer Drug Development JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 726 OP 732 DO 10.2967/jnumed.116.188045 VO 59 IS 5 A1 Stijn J.H. Waaijer A1 Iris C. Kok A1 Bertha Eisses A1 Carolina P. Schröder A1 Mathilde Jalving A1 Adrienne H. Brouwers A1 Marjolijn N. Lub-de Hooge A1 Elisabeth G.E. de Vries YR 2018 UL http://jnm.snmjournals.org/content/59/5/726.abstract AB Development of new oncology drugs has increased since the improved understanding of cancer’s complex biology. The oncology field has become the top therapeutic research area for new drugs. However, only a limited number of drugs entering clinical trials will be approved for use as the standard of care for cancer patients. Molecular imaging is increasingly perceived as a tool to support go/no-go decisions early during drug development. It encompasses a wide range of techniques that include radiolabeling a compound of interest followed by visualization with SPECT or PET. Radiolabeling can be performed using a variety of radionuclides, which are preferably matched to the compound on the basis of size and half-life. Imaging can provide information on drug behavior in vivo, whole-body drug target visualization, and heterogeneity in drug target expression. This review focuses on current applications of molecular imaging in the development of small molecules, antibodies, and antihormonal anticancer drugs.